Association of tobacco exposure and reduction of radiographic progression in early rheumatoid arthritis: Results from a French multicenter cohort

Arthritis Care and Research

Volumn 65, Issue 12, 2013, Pages 1899-1906

  Vesperini, Veronique ^a   Lukas, Cedric ^a   Fautrel, Bruno ^b   Le Loet, Xavier ^c   Rincheval, Nathalie ^d   Combe, Bernard ^a  

^a LAPEYRONIE HOSPITAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c Dept de Médecine Interne Ctr Hosp Univ Rouen Boisguillaume   (France)

^d Laboratory of Biostatistics and Epidemiology   (France)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HLA DRB1 ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RHEUMATOID FACTOR;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOLOGICAL THERAPY; CORTICOSTEROID THERAPY; DAS28; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RADIOGRAPHY; REMISSION; RHEUMATOID ARTHRITIS; SMOKING; SMOKING CESSATION; SMOKING HABIT; TREATMENT RESPONSE;

ARTHRITIS, RHEUMATOID; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; SMOKING;

EID: 84889067649     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22057     Document Type: Article

References (40)

1. Sugiyama D, Nishimura K, Tamaki K, Tsuji G, Nakazawa T, Morinobu A, et al, Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2010; 69: 70-81.
2. Mattey DL, Hutchinson D, Dawes PT, Nixon NB, Clarke S, Fisher J, et al. Smoking and disease severity in rheumatoid arthritis: association with polymorphism at the glutathione S-transferase M1 locus. Arthritis Rheum 2002; 46: 640-6.
3. Nyhall-Wahlin BM, Petersson IF, Nilsson JA, Jacobsson LT, Turesson C,. High disease activity disability burden and smoking predict severe extra-articular manifestations in early rheumatoid arthritis. Rheumatology (Oxford) 2009; 48: 416-20.
4. Papadopoulos NG, Alamanos Y, Voulgari PV, Epagelis EK, Tsifetaki N, Drosos AA,. Does cigarette smoking influence disease expression, activity and severity in early rheumatoid arthritis patients? Clin Exp Rheumatol 2005; 23: 861-6.
5. Wolfe F,. The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis. J Rheumatol 2000; 27: 630-7.
6. Harrison BJ, Silman AJ, Wiles NJ, Scott DG, Symmons DP,. The association of cigarette smoking with disease outcome in patients with early inflammatory polyarthritis. Arthritis Rheum 2001; 44: 323-30.
7. Linn-Rasker SP, van der Helm-van Mil AH, van Gaalen FA, Kloppenburg M, de Vries RR, le Cessie S, et al. Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis 2006; 65: 366-71.
8. Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006; 54: 38-46.
9. Van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Huizinga TW, Toes RE, de Vries RR,. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum 2006; 54: 1117-21.
10. Verpoort KN, Papendrecht-van der Voort EA, van der Helm-van Mil AH, Jol-van der Zijde CM, van Tol MJ, Drijfhout JW, et al. Association of smoking with the constitution of the anti-cyclic citrullinated peptide response in the absence of HLA-DRB1 shared epitope alleles. Arthritis Rheum 2007; 56: 2913-8.
11. Lee HS, Irigoyen P, Kern M, Lee A, Batliwalla F, Khalili H, et al. Interaction between smoking, the shared epitope, and anti-cyclic citrullinated peptide: a mixed picture in three large North American rheumatoid arthritis cohorts. Arthritis Rheum 2007; 56: 1745-53.
12. Klareskog L,. Rheumatoid arthritis. Lancet 2009; 373: 659-72.
13. Masdottir B, Jonsson T, Manfredsdottir V, Vikingsson A, Brekkan A, Valdimarrsson H,. Smoking, rheumatoid factor isotypes and severity of rheumatoid arthritis. Rheumatology (Oxford) 2000; 39: 1202-5.
14. Mattey DL, Brownfield A, Dawes PT,. Relationship between pack-year history of smoking and response to tumor necrosis factor antagonists in patients with rheumatoid arthritis. J Rheumatol 2009; 36: 1180-7.
15. Westhoff G, Rau R, Zink A,. Rheumatoid arthritis patients who smoke have a higher need for DMARDs and feel worse, but they do not have more joint damage than non-smokers of the same serological group. Rheumatology (Oxford) 2008; 47: 849-54.
16. Saag KG, Cerhan JR, Kolluri S, Ohashi K, Hunninghake GW, Schwartz DA,. Cigarette smoking and rheumatoid arthritis severity. Ann Rheum Dis 1997; 56: 463-9.
17. Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B,. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 2004; 63: 1090-5.
18. Finckh A, Dehler S, Costenbader KH, Gabay C,. Cigarette smoking and radiographic progression in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 1066-71.
19. Manfredsdottir VF, Vikingsdottir T, Jonsson T, Geirsson AJ, Kjartansson O, Heimisdottir M, et al. The effects of tobacco smoking and rheumatoid factor seropositivity on disease activity and joint damage in early rheumatoid arthritis. Rheumatology (Oxford) 2006; 45: 734-40.
20. Combe B, Benessiano J, Berenbaum F, Cantagrel A, Daures J, Dougados M, et al. The ESPOIR cohort: a ten-year follow-up of early arthritis in France: methodology and baseline characteristics of the 813 included patients. Joint Bone Spine 2007; 74: 440-5.
21. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569-81.
22. Lukas C, Combe B, Ravaud P, Sibilia J, Landew R, van der Heijde D,. Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: data from the Etude et Suivi des polyarthrites indifferenciees recentes (study and followup of early undifferentiated polyarthritis). Arthritis Rheum 2011; 63: 1804-11.
23. Wolfe F, Zwillich SH,. The long-term outcomes of rheumatoid arthritis: a 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. Arthritis Rheum 1998; 41: 1072-82.
24. Drossaers-Bakker KW, de Buck M, van Zeben D, Swinderman AH, Breedveld FC, Hazes JM,. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum 1999; 42: 1854-60.
25. Hyrich KL, Watson KD, Silman AJ, Symmons D,. Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006; 45: 1558-65.
26. Mikuls TR, Hughes LB, Westfall AO, Holers VM, Parrish L, van der Heijde, et al. Cigarette smoking, disease severity and autoantibody expression in African Americans with recent-onset rheumatoid arthritis. Ann Rheum Dis 2008; 67: 1529-34.
27. Sokjer M, Jonsson M, Bodvarsson S, Jonsdottir I, Valdimarsson H,. Selective increase of IgA rheumatoid factor in patients with gluten sensitivity. Acta Derm Venereol 1995; 75: 130-2.
28. Wessels JA, van der Kooij SM, le Cessie S, Kievit W, Barerra P, Allaart CF, et al, for the Pharmacogenetics Collaborative Research Group. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum 2007; 56: 1765-75.
29. Saevarsdottir S, Wedren S, Seddighzadeh M, Bengtsson C, Wesley A, Lindblad S, et al. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis Rheum 2011; 63: 26-36.
30. Soderlin M, Geborek P,. Intensity of smoking (pack-years) is associated with poor therapy response in RA patients starting their first anti-TNF treatment: data from SSATG, a biologics register in southern Sweden [abstract]. Ann Rheum Dis 2010; Suppl 3: 54.
31. Fisher MC, El-Taha M, Kremer JM, Peng C, Greenberg J,. Smoking cessation and improvement in RA disease activity [abstract]. Arthritis Rheum 2008; 58 Suppl: S610.
32. Arnson Y, Shoenfeld Y, Amital H,. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 2010; 34: J258-65.
33. Spector TD, Blake DR,. Effect of cigarette smoking on Langerhans' cells [abstract]. Lancet 1988; 2: 1028.
34. Kalayciyan A, Orawa H, Fimmel S, Perschel FH, Gonzalez JB, Fitzner RG, et al. Nicotine and biochanin A, but not cigarette smoke, induce anti-inflammatory effects on keratinocytes and endothelial cells in patients with Behçet's disease. J Invest Dermatol 2007; 127: 81-9.
35. Zoppini G, Faccini G, Muggeo M, Zenari L, Falezza G, Targher G,. Elevated plasma levels of soluble receptors of TNF-α and their association with smoking and microvascular complications in young adults with type 1 diabetes. J Clin Endocrinol Metab 2001; 86: 3805-8.
36. Lindblad SS, Mydel P, Jonsson IM, Senior RM, Tarkowski A, Bokarewa M,. Smoking and nicotine exposure delay development of collagen-induced arthritis in mice. Arthritis Res Ther 2009; 11: R88.
37. McGilligan VE, Wallace JM, Heavey PM, Ridley DL, Rowland IR,. Hypothesis about mechanisms through which nicotine might exert its effect on the interdependence of inflammation and gut barrier function in ulcerative colitis. Inflamm Bowel Dis 2007; 13: 108-15.
38. Nizri E, Irony-Tur-Sinai M, Lory O, Orr-Urtreger A, Lavi E, Brenner T,. Activation of the cholinergic anti-inflammatory system by nicotine attenuates neuroinflammation via suppression of Th1 and Th17 responses. J Immunol 2009; 183: 6681-8.
39. Yu H, Yang YH, Rajaiah R, Moudgil KD,. Nicotine-induced differential modulation of autoimmune arthritis in the Lewis rat involves changes in interleukin-17 and anti-cyclic citrullinated peptide antibodies. Arthritis Rheum 2011; 63: 981-91.
40. Miao FJ, Green PG, Benowitz N, Levine JD,. Central terminals of nociceptors are targets for nicotine suppression of inflammation. Neuroscience 2004; 123: 777-84.